References
- 1. Bauer S. et al.: Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. J. Diabetes Complications, 2011, 25:377-381.10.1016/j.jdiacomp.2011.06.001
- 2. Cao H., Hegele R.: Single nucleotide polymorphisms of the resistin (RSTN) gene. J. Hum Genet., 2001; 46: 553-555.
- 3. Ebtesam A Al-Suhaimi, Adeeb Shehzad.: Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. European Journal of Medical Research, 2013, 18:12.10.1186/2047-783X-18-12
- 4. Fujinami A. et al.: Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clinica Chimica Acta, 2004; 339 (1-2): 57-63.10.1016/j.cccn.2003.09.009
- 5. Hasegawa G., et al.: Plasma concentrations of resistin in type 2 diabetic patients. Diabetes, 2003; 52 (1): 82-83.
- 6. Janke J. et al.: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes. Res., 2002; 10: 1-5.10.1038/oby.2002.1
- 7. Jinhua Yin et al.: Measurement of Salivary Resistin Level in Patients with Type 2 Diabetes. International Journal of Endocrinology, 2012; 2012: Article ID 359724, 5 p.10.1155/2012/359724
- 8. Lauders M et al.: Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res., 2010 Apr;42(4):268-7310.1055/s-0029-1243638
- 9. Lee J.H. et al.: Circulating resistin levels are not associated with obesity or insulin resistance in humans, and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab., 2003; 88: 4848-4856.10.1210/jc.2003-030519
- 10. McTernan C.L. et al.: Resistin, central obesity, and type 2 diabetes. Lancet, 2002; 36: 46-7.10.1016/S0140-6736(02)07281-1
- 11. Meier U., Gressner A.M.: Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem., 2004; 50: 1511-1525.
- 12. Nagaev I, Smith U.: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem. Biophys. Res. Commun., 2001; 285: 561-564.
- 13. Rajala M. et al.: Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes, 2004; 53 (7): 1671-1679.10.2337/diabetes.53.7.167115220189
- 14. Rangwala S. et al.: Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes, 2004; 53: 1937-1941.10.2337/diabetes.53.8.193715189975
- 15. Shuldier A., Yang R., Gong D.W.: Resistin, obesity and insulin resistance. N Engl J Med., 2001; 345: 1345-1346.
- 16. Steppan C.M. et al.: The hormone resistin links obesity to diabetes. Nature, 2001; 409: 307-12.10.1038/3505300011201732
- 17. Tokuyama Y. et al.: Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus. Metabolism, 2007; 56 (5): 693-698.10.1016/j.metabol.2006.12.01917445546
- 18. Vozarova De Courten B. et al.: High serum resistin is associated with an increase in adiposity but not worsening of insulin resistance in Pima Indian. Diabetes, 2004; 53 (9): 1279-1284.10.2337/diabetes.53.5.127915111497